APL Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: APL Healthcare Limited Pharmaceutical Export Portfolio Dataset — 17 Products, $27.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

APL Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 17 Products, $27.3M Trade | TransData Nexus

APL Healthcare Limited

Indian Pharmaceutical Exporter · CNS & Psychiatric Specialist · $27.3M Total Trade · DGFT Verified

APL Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $27.3M across 17 products in 11 therapeutic categories. Based on 592 verified export shipments from Indian Customs (DGFT) records, APL Healthcare Limited is the #1 Indian exporter in 1 product including Lorazepam. Top exports include Sertraline ($5.8M), Potassium ($4.0M), Fluoxetine ($3.6M).

APL Healthcare Limited — Export Portfolio & Destination Treemap

APL Healthcare Limited pharmaceutical export portfolio — 17 products across 11 therapeutic categories. Source: Indian Customs (DGFT).

Who is APL Healthcare Limited? — Company Overview & Market Position

APL Healthcare Limited is a public limited company incorporated on December 19, 2006, under the Corporate Identification Number (CIN) U24239TG2006PLC052053. The company is registered with the Registrar of Companies in Hyderabad, Telangana, India. Its registered office is located at Plot No. 2 Maithri Vihar, Ameerpet, Hyderabad, Telangana, 500038, India.

The authorized capital of APL Healthcare Limited is ₹240 crore, with a paid-up capital of ₹216 crore, reflecting a 92.5% paid-up ratio. The company is primarily engaged in the manufacturing of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. As of March 2026, APL Healthcare Limited has a workforce of approximately 500 employees.

What Does APL Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sertraline$5.8M 2Potassium$4.0M

Product Portfolio — Top 17 by Export Value

APL Healthcare Limited exports 17 pharmaceutical products across 11 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sertraline	CNS & Psychiatric	$5.8M	115	1.0%	5
2	Potassium	Nutritional Supplements	$4.0M	81	0.6%	12
3	Fluoxetine	CNS & Psychiatric	$3.6M	73	1.5%	9
4	Tenofovir	Antiviral & HIV Medications	$2.6M	53	0.1%	8
5	Dolutegravir	Antiviral & HIV Medications	$2.5M	51	0.1%	6
6	Losartan	Cardiovascular	$1.9M	38	0.6%	10
7	Prednisone	Respiratory	$1.2M	32	4.5%	5
8	Famotidine	Gastrointestinal	$1.0M	20	1.8%	12
9	Lorazepam	CNS & Psychiatric	$947.1K	19	37.7%	1
10	Sulfamethoxazole	Advanced Antibiotics	$891.1K	25	4.5%	4
11	Trimethoprim	Advanced Antibiotics	$891.1K	25	3.4%	6
12	Clonazepam	CNS & Psychiatric	$812.5K	35	0.6%	4
13	Darunavir	Antiviral & HIV Medications	$350.0K	7	0.6%	7
14	Dapagliflozin	Advanced Diabetes Medications	$300.0K	6	0.6%	10
15	Leflunomide	Immunosuppressants	$151.8K	5	1.0%	13
16	Pyrimethamine	Antimalarial & Antiparasitic	$150.0K	3	0.3%	6
17	Pseudoephedrine	Respiratory & OTC	$93.2K	4	0.8%	8

APL Healthcare Limited exports 17 pharmaceutical products across 11 therapeutic categories with a total export value of $27.3M. The company is the #1 Indian exporter in 1 product: Lorazepam. The top category is CNS & Psychiatric (40.6% of portfolio), followed by Antiviral & HIV Medications (20.3%), indicating a concentrated portfolio with the top 5 products accounting for 68.0% of total export value.

APL Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

APL Healthcare Limited operates manufacturing facilities in Hyderabad, Telangana, India. These facilities are equipped to produce a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. The company has invested in state-of-the-art equipment and adheres to stringent quality control measures to ensure the production of high-quality pharmaceutical formulations. Specific details regarding the capacities and specializations of these manufacturing plants are not publicly disclosed.

3Key Leadership

The leadership team at APL Healthcare Limited comprises several key executives:

Nityananda Reddy Kambam: Director since December 19, 2006.

Sivakumaran Meenakshisunderam: Director since December 19, 2006.

Sarath Chandra Reddy Penaka: Director since November 25, 2009.

Kondreddy Venkateswara Rao: Director since March 30, 2015.

Vinod Kumar Reddy Aerva: Director since March 30, 2015.

Suryanarayana Murthy Mula: Chief Financial Officer (CFO) since July 1, 2021.

Venkatanarayana Reddy Jayampu: Whole-Time Director since May 23, 2019.

Mylandlahalli Rammohan Ashwini: Director since May 17, 2024.

Salgunan Komatheruvan Chettivalappil: Company Secretary since February 1, 2022.

These individuals collectively contribute to the strategic direction and operational management of APL Healthcare Limited.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does APL Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

APL Healthcare Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its pharmaceutical products in these regions, ensuring compliance with the respective health authorities' standards. APL Healthcare Limited has filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for various products, facilitating market access in the United States. In the European Union and the United Kingdom, the company has secured marketing authorizations for its products, adhering to the European Medicines Agency (EMA) and Medicines and Healthcare products Regulatory Agency (MHRA) guidelines. APL Healthcare Limited has also obtained necessary approvals from the Therapeutic Goods Administration (TGA) in Australia and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, enabling the distribution of its products in these markets.

2Emerging Markets

APL Healthcare Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company has achieved World Health Organization (WHO) prequalification for several of its products, facilitating access to these regions. This prequalification ensures that APL Healthcare Limited's products meet international quality standards, enhancing their acceptance in these markets. The company's strategic focus on emerging markets aligns with its objective to diversify its global presence and tap into the growing demand for affordable and quality healthcare solutions.

APL Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

APL Healthcare Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's regulations for pharmaceutical manufacturing. The company has filed multiple Abbreviated New Drug Applications (ANDAs) for its products, facilitating market entry in the United States. APL Healthcare Limited's facilities have undergone FDA inspections, and the company has maintained a satisfactory inspection history, reflecting its commitment to adhering to FDA standards. The company's proactive approach to regulatory compliance underscores its dedication to delivering safe and effective pharmaceutical products to the U.S. market.

2WHO & EU GMP

APL Healthcare Limited has achieved World Health Organization (WHO) prequalification for several of its pharmaceutical products, indicating that they meet international quality standards. This prequalification facilitates the company's access to various global markets, particularly in developing regions. In addition, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating compliance with the stringent manufacturing standards set by the European Medicines Agency (EMA). These certifications reflect APL Healthcare Limited's commitment to maintaining high-quality manufacturing processes and ensuring the safety and efficacy of its products.

APL Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

APL Healthcare Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. In the generic pharmaceutical segment, the company competes with other Indian manufacturers such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Cipla, which have established global presences. APL Healthcare Limited differentiates itself through its focus on finished pharmaceutical formulations and its strategic expansion into emerging markets. The company's ability to obtain WHO prequalification and EU GMP certifications enhances its competitiveness, enabling it to meet international quality standards and access a broader range of markets.

2Key Differentiators

APL Healthcare Limited's key differentiators include its comprehensive portfolio of finished pharmaceutical formulations, encompassing 17 products across 11 therapeutic categories. The company's top five products—Sertraline, Potassium, Fluoxetine, Tenofovir, and Dolutegravir—collectively account for 68% of its export value, indicating a strong focus on high-demand medications. APL Healthcare Limited's leadership in Lorazepam production further distinguishes it in the market. The company's strategic emphasis on obtaining international certifications, such as WHO prequalification and EU GMP, underscores its commitment to quality and regulatory compliance, enhancing its reputation among global stakeholders.

Buyer Due Diligence Brief — Evaluating APL Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

APL Healthcare Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $27.3 million USD across 592 shipments from 2022 to 2026. The company's portfolio includes 17 products spanning 11 therapeutic categories, indicating a diversified product range.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — APL Healthcare Limited

How many pharmaceutical products does APL Healthcare Limited export from India?

APL Healthcare Limited exports 17 pharmaceutical products across 11 therapeutic categories. The top exports are Sertraline ($5.8M), Potassium ($4.0M), Fluoxetine ($3.6M), Tenofovir ($2.6M), Dolutegravir ($2.5M). Total export value is $27.3M.

What is APL Healthcare Limited's total pharmaceutical export value?

APL Healthcare Limited's total pharmaceutical export value is $27.3M, based on 592 verified shipments recorded in Indian Customs (DGFT) data.

In which products is APL Healthcare Limited the #1 Indian exporter?

APL Healthcare Limited is the #1 Indian exporter in 1 products: Lorazepam (37.7% market share).

What therapeutic categories does APL Healthcare Limited cover?

APL Healthcare Limited exports across 11 therapeutic categories. The largest are CNS & Psychiatric (40.6%, 4 products), Antiviral & HIV Medications (20.3%, 3 products), Nutritional Supplements (14.8%, 1 products).

Get Full APL Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.